Lupin sees highest patent filings and grants during September in Q3 2023
Lupin saw the highest growth of 199% in patent filings in August and 149% in grants in July in Q3 2023. Compared to Q2 2023, Q3 2023 saw an increase in patent filings by 66% and grants by 149%. GlobalData's DataBook provides a comprehensive analysis of Lupin's patent filings and grants. Buy the databook here.Lupin has been focused on protecting inventions in Canada(CA) with 3 publications in Q3 2023The Canada(CA) Patent Office dominates the patent filings and grants with nearly 0% filings and 43% grants. The China(CN), European Patent Office(EPO), Israel(IL), and Canada(CA) patent Office are among the top ten patent offices where Lupin is filings its patents. Among the top granted patent authorities, Lupin has 43% of its grants in Canada(CA), 29% in Taiwan(TW), and 14% in China(CN).Johnson & Johnson could be the strongest competitor for LupinJohnson & Johnson and Pfizer secured the top positions according to recent patent publication data.Patents related to mobile and lead Lupin's portfolioLupin has the highest number of patents in mobile followed by, and . For mobile, nearly 0% of patents were filed and 100% of patents were granted in Q3 2023.Leukemia related patents lead Lupin portfolio followed by pancreatic cancer, and bacterial vaginosisLupin has highest number of patents in leukemia followed by pancreatic cancer, bacterial vaginosis, human immunodeficiency virus (hiv) infections (aids) and lymphoma. For leukemia, nearly 0% of patents were filed and 0% of patents were granted in Q3 2023.For comprehensive analysis of Lupin's filings and grants, buy the databook here.
Access and buy GlobalData’s databook on the latest filings and grants activity for Lupin here.
What's Your Reaction?
